Russian multicentre type 2 diabetes screening program in patients with cardiovascular disease

Código QR

Russian multicentre type 2 diabetes screening program in patients with cardiovascular disease

Aim.To evaluate the prevalence of undiagnosed type 2 diabetes mellitus (T2DM) among patients with cardiovascular disease.Materials and methods.T2DM screening programs among patients with cardiovascular disease were held from 2013 to 2014 in several Russian cities. In total, 1001 patients aged ≥40 ye...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marina Vladimirovna Shestakova, Irina Evgenievna Chazova, Ekaterina Alekseevna Shestakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	type 2 diabetes mellitus cardiovascular disease screening Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/509d26ab7ad2486b8de05d8c68fd0fee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Expert council resolution on regional program of early T2D detection, prevention and treatment in Russian Federation
por: Marina V. Shestakova, et al.
Publicado: (2017)

Pharmacoeconomic assessment of type 2 diabetes mellitus care on the base of Endocrinology Research Centre, Moscow
por: Ivan Ivanovich Dedov, et al.
Publicado: (2012)

A1chieve Program in Russian Federation: a multicenter prospective observational study of insulin analogue treatment efficiency and safety in daily management of patients with type 2 diabetes mellitus, who startand intensify insulin treatment having never received it before
por: Marina Vladimirovna Shestakova
Publicado: (2012)

Diabetes mellitus type 2: a new indication for hypercortisolism screening?
por: Natalya Ivanovna Volkova, et al.
Publicado: (2012)

Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2010)

Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL
por: Marina Vladimirovna Shestakova
Publicado: (2011)

IMPROVE observational program: safety and effectiveness of biphasic insulin aspart 30 in routine clinical practice. Overview of starting characteristics of the Russian patient cohort
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2009)

Glibenclamide therapy: pros and cons
por: Olga Konstantinovna Vikulova, et al.
Publicado: (2011)

Can simple intensification of therapy with modern two-phase insulin help in type 2 diabetes when target glycemia failed to be achieved withbasal insulin? Results of subanalysis in the PRESENT study
por: Ch S Yang, et al.
Publicado: (2009)

Pharmacogenetics of hypoglycemic agents
por: Irina Vladimirovna Kononenko, et al.
Publicado: (2015)

Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation
por: Ivan I. Dedov, et al.
Publicado: (2016)

The results of open observational trial DIAMOND
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2011)

New indications for exenatide therapy of type 2 diabetes mellitus
por: Olga Konstantinovna Vikulova, et al.
Publicado: (2010)

Obesity - a risk factor of renal pathology in patients with type 2 diabetes mellitus
por: Svetlana Alekseevna Savel'eva, et al.
Publicado: (2010)

Diabetes mellitus as an economic problem in Russian Federation
por: Ivan Ivanovich Dedov, et al.
Publicado: (2016)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
por: Ekaterina Alekseevna Shestakova
Publicado: (2011)

Early insulin therapy Coordination Council
por: Marina Vladimirovna Shestakova
Publicado: (2012)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
por: Olga Yuryevna Sukhareva, et al.
Publicado: (2016)

Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2010)

National register of diabetes mellitus in Russian Federation.
por: Ivan Ivanovich Dedov, et al.
Publicado: (2015)

Evaluation of the degree of metabolic compensation and prevalence of diabetic complications in a Russian population of childrenand adolescents (results of the ?Screening for diabetic complications and assessment of medical aid to diabetic patients? Project)
por: Ekaterina Andreevna Andrianova, et al.
Publicado: (2009)

Cardiorenal relationships in patients with type 2 diabetes mellitus: new data of the ADVANCE study
por: Marina Vladimirovna Shestakova
Publicado: (2009)

Results of the ADVANCE trial and interventional observational program ADVANCE-ON: whether our understanding of the relationship of glycemic factors and the risk of vascular complications in patients with type 2 diabetes has changed?
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2015)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
por: Marina V. Shestakova, et al.
Publicado: (2017)

Efficacy and safety of treatment with human insulin analogues in daily management of insulin naive patients with type 2 diabetes mellitus: results of multicenter 52-week observational study A1chive
por: Marina Vladimirovna Shestakova
Publicado: (2012)

Изучение количества циркулирующих прогениторных клеток эндотелия у больных сахарным диабетом 1 типа
por: Angelina Valerievna Sokolova, et al.
Publicado: (2015)

Optimizing screening procedures for early detection of glycemic disorders
por: Inna Vladimirovna Misnikova, et al.
Publicado: (2014)

Friedreichs ataxia in a diabetic patient
por: Inna Igorevna Klefortova, et al.
Publicado: (2010)

Modern approach to basal-bolus therapy with glargine and glulisine insulin analoguesin various age groups
por: Natalya Nikitichna Volevodz, et al.
Publicado: (2013)

«DIARISK» — the first national prediabetes and diabetes mellitus type 2 risk calculator
por: Marina V. Shestakova, et al.
Publicado: (2021)

Prevalence of renal lesions in patients with type 1 and 2 diabetes mellitus in the Russian Federation
por: Oksana Vladimirovna Maslova, et al.
Publicado: (2009)

Novosti fundamental'nykh issledovaniy
por: Ivona Renata Yarek-Martynova, et al.
Publicado: (2008)

Obesity and type 2 diabetes: can we find a compromised treatment solution?
por: Gagik R. Galstyan, et al.
Publicado: (2017)

Stratification of patients with type 2 diabetes mellitus for painless ischemic heart disease
por: Natalya Ivanovna Volkova, et al.
Publicado: (2012)

Comments on the Consensus statement of the American Diabetes Association and the European Association for the Studyof Diabetes on the medical management of hyperglycemia in type 2 diabetes
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009)

Materials of the congress CHD and peripheral atherosclerosis treatment in diabetic patients
por: Victor Yur'evich Kalashnikov, et al.
Publicado: (2012)

Signaling pathways of β-cell death in type 2 diabetes mellitus: the role of innate immunity
por: Zilya. A. Kalmykovа, et al.
Publicado: (2020)

Epidemiology and ecology of type 1 diabetes mellitus in children and adolescents of Krasnodar Region
por: Irina Yur'evna Chernyak, et al.
Publicado: (2013)

Consensus statement by a panel of experts of the Russian Association of Endocrinologists (RAE) on initiation and intensificationof hypoglycemic therapy for type 2 diabetes mellitus
por: Ivan Ivanovich Dedov, et al.
Publicado: (2011)